The PIP Secretariat and PIP Advisory Group regularly report to the World Health Assembly (WHA) and to the Executive Board (EB). In addition, the WHA and EB have adopted a number of decisions and resolutions relevant to the PIP Framework.

At the 152nd meeting of the WHO Executive Board, it was decided to maintain the current proportional allocation of the Partnership Contribution resources between preparedness and response, as required under the Pandemic Influenza Preparedness Framework, Section 6.14.5, until 31 December 2030.

At the Seventy-Second World Health Assembly in May 2019, Member States adopted Decision WHA72(12), which made a number of requests to the Director-General related to, among other things, influenza virus sharing, genetic sequence data, and the Standard Material Transfer Agreement 2 (SMTA2)

At the request of the Seventieth World Health Assembly in May 2017, the Director-General conducted an Analysis of the implications of pursuing or not pursuing possible approaches to seasonal influenza viruses and GSD under the PIP Framework. The Analysis, along with accompanying information, is available at the following link:

The Advisory Group (AG) is a group of 18 independent technical experts who monitor the PIP Framework and advise the WHO Director-General on its functioning.

The PIP AG meets twice each year in Geneva to monitor developments and to provide recommendations to the Director-General. More information on the PIP Advisory Group, including its Members, Reports, and work in various technical areas is available at the link below.

Genetic sequence data (GSD) are the order of nucleotides found in a molecule of DNA or RNA. They contain the genetic information that determines the biological characteristics of an organism or a virus. In the case of influenza viruses, this can include characteristics such as pathogenicity, transmissibility and antiviral susceptibility.

GSD derived from influenza viruses with human pandemic potential (IVPP) are included under the PIP Framework, but not in the definition of PIP BM. While access to physical viruses (PIP BM) requires signing an SMTA2 and is linked to payment of the Partnership Contribution, access to IVPP GSD is only linked to payment of the Partnership Contribution.

In 2016 the PIP Framework underwent its first comprehensive review. A group of 8 independent experts was convened to assess what the PIP Framework had achieved so far, and what were the challenges and possible ways of addressing them.

The Review Group began its work in January 2016 and provided its final report in October 2016, for transmission to the 142nd Executive Board in January 2017. The Review Group's recommendations and implementation status can be found here.